Insights Into the Recognition and Management of SGLT2-Inhibitor-Associated Ketoacidosis: It's Not Just Euglycemic Diabetic Ketoacidosis

Can J Diabetes. 2017 Oct;41(5):499-503. doi: 10.1016/j.jcjd.2017.05.004. Epub 2017 Aug 7.

Authors

Stephanie Dizon¹, Erin J Keely², Janine Malcolm², Amel Arnaout²

Affiliations

¹ University of Ottawa, Department of Medicine, Division of Endocrinology & Metabolism, Ottawa, Ontario, Canada; The Ottawa Hospital, Ottawa, Ontario, Canada. Electronic address: sdizon@toh.ca.
² University of Ottawa, Department of Medicine, Division of Endocrinology & Metabolism, Ottawa, Ontario, Canada; The Ottawa Hospital, Ottawa, Ontario, Canada.

PMID: 28797889
DOI: 10.1016/j.jcjd.2017.05.004

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Aged
Diabetes Mellitus, Type 2 / drug therapy*
Diabetic Ketoacidosis / chemically induced
Diabetic Ketoacidosis / diagnosis
Diabetic Ketoacidosis / therapy*
Disease Management
Fluid Therapy
Humans
Hypoglycemic Agents / adverse effects*
Ketosis / chemically induced
Ketosis / diagnosis
Ketosis / therapy*
Male
Middle Aged
Prognosis
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors*

Substances

Hypoglycemic Agents
SLC5A2 protein, human
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors